Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025
  • H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025
  • Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – ir@ionis.com760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – media@ionis.com – 760-603-4679

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.14
+3.71 (1.62%)
AAPL  272.36
+1.39 (0.51%)
AMD  214.90
-0.05 (-0.02%)
BAC  55.97
+0.09 (0.16%)
GOOG  315.68
+4.35 (1.40%)
META  664.94
+3.44 (0.52%)
MSFT  486.85
+1.93 (0.40%)
NVDA  189.21
+5.52 (3.01%)
ORCL  195.34
-3.04 (-1.53%)
TSLA  485.56
-3.17 (-0.65%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.